| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier Free | 293-VE-001MG/CF | |||
| Carrier Free | 293-VE-010/CF | |||
| Carrier Free | 293-VE-050/CF | |||
| Carrier Free | 293-VE-500/CF | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier Free | AF-493-SP | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier Free | MAB293-SP | |||
| Carrier Free | MAB293-500 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB100-664SS | |||
| Azide and BSA Free | NBP2-81007 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier Free | AF-293-SP | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier Free | 493-MV-005/CF | |||
| Carrier Free | 493-MV-025/CF | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier Free | 493-MV-025/CF | |||
![N/A VEGF [HRP]](http://images.novusbio.com/fullsize2/DATA_VEGF_DVE00_ELISA_871.jpg "N/A VEGF [HRP]")
![N/A VEGF [HRP]](http://images.novusbio.com/fullsize2/DATA_VEGF_DVE00_ELISA_872.jpg)
![N/A VEGF [HRP]](http://images.novusbio.com/fullsize2/VEGF_DVE00_ELISA_208.jpg)
![N/A VEGF [HRP]](http://images.novusbio.com/fullsize2/DATA_VEGF_MMV00_ELISA_1008.jpg "N/A VEGF [HRP]")
![N/A VEGF [HRP]](http://images.novusbio.com/fullsize2/VEGF_MMV00_ELISA_298.jpg)
![N/A VEGF [Biotin]](http://images.novusbio.com/fullsize2/DATA_VEGF_DY293_ELISA_2316.jpg "N/A VEGF [Biotin]")
![Immunohistochemistry: VEGF Antibody (VG1) - BSA Free [NB100-664] - HPG induces less VEGF production, less myofibroblast differentiation and lower macrophage activation. The expression of VEGF, alpha-SMA and MAC387 in the peritoneal tissue sections was examined using a routine immunohistochemical method. Data were a typical microscopic view of the peritoneal tissue sections in each group. a VEGF was detected using mouse monoclonal anti-VEGF antibody from Novus. Left graph a typical microscopic view, Dark brown stain VEGF-expressing cells (pointed by red arrows), Bv blood vessels, M muscle, black small bar 10 um. Right graph VEGF-expressing cells per 200 um PM length in cross sections. Data were presented as mean +/- SD (n = 6) and were analyzed using t test. Image collected and cropped by CiteAb from the following publication (//translational-medicine.biomedcentral.com/articles/10.1186/s12967-016-1098-z) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/VEGF-Antibody-VG1-BSA-Free-Immunohistochemistry-NB100-664-img0015.jpg)
![Western Blot: VEGF Antibody (VG1) - BSA Free [NB100-664] - Regorafenib transcriptionally inhibited VEGF-A expression through decreasing binding of STAT3 on promoter of VEGF-A.(A) Top, MDA-MB-231 cells co-transfected w/ a Renilla control vector & plasmids containing firefly luciferase gene driven by wild-type or STAT3 binding site-mutated VEGF-A promoter. After transfection for 48 h, cells treated w/ regorafenib for 24 h. Promoter activity analyzed by luciferase assay after regorafenib treatment. Bottom, MDA-MB-231 cells transfected w/ vector-control or STAT3-overexpression plasmid for 48 h. After , cells further co-transfected w/ Renilla & wild-type VEGF-A promoter & detect promoter activity as mentioned above. *p < 0.05, **p < 0.01. (B) After regorafenib treatment for 24 h, STAT3 binding site fragment detected by PCR in ChIP samples precipitated w/ STAT3 & rabbit IgG control antibodies in MDA-MB-231 cells. (C,D), MDA-MB-231 cells transfected, respectively, w/ control vector or VEGF-A overexpression plasmid (C) or STAT3 overexpression plasmid (D) for 48 h. After transfection, cells treated w/wo regorafenib for 24 h & subjected to WB assay or seeded to Transwell to analyze migration ability. *p < 0.05, **p < 0.01. (E) Cells treated w/ regorafenib at indicated dosages for 24 h & cell lysates analyzed by SHP-1 phosphatase activity assay. *p < 0.05, **p < 0.01. (F) MDA-MB-231 cells pretreated w/ pan-phosphatase inhibitor (left), or specific SHP-1 inhibitor (Middle) for 1 h before regorafenib treatment. Right, MDA-MB-231 cells transfected, respectively, w/ control siRNA or SHP-1 siRNA for 48 h. After transfection, cells treated w/wo regorafenib (10 μM) for 24 h. The protein levels analyzed by WB assay or cells seeded to Transwell to analyze migration ability. *p < 0.05, **p < 0.01. Image collected & cropped by CiteAb from following publication (//pubmed.ncbi.nlm.nih.gov/27364975), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-664_mouse-monoclonal-vegf-antibody-vg1-31020241682159.jpg)
![N/A VEGF [HRP]](http://images.novusbio.com/fullsize2/DATA_VEGF_RRV00_ELISA_1097.jpg "N/A VEGF [HRP]")
![N/A VEGF [HRP]](http://images.novusbio.com/fullsize2/DATA_VEGF_RRV00_ELISA_1098.jpg)
![N/A VEGF [HRP]](http://images.novusbio.com/fullsize2/VEGF_RRV00_ELISA_364.jpg)
![N/A VEGF [Biotin]](http://images.novusbio.com/fullsize2/DATA_VEGF_DY493_ELISA_2066.jpg "N/A VEGF [Biotin]")